ClinicalTrials.gg
CompletedNCT03764475Updated Sep 2, 2022Results posted

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

A Phase 2 interventional study of Roflumilast in Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
332
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.

Enrollment
5th of 17
332 · median 46
Started
2018
with 1 other
Phase 2
7 of 17
1 open now
Registered
4th of 17
by date
Lead sponsor
9 of 17
Arcutis Biotherapeutics, Inc.

Among the 17 studies testing roflumilast in Psoriasis, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 2, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing roflumilast in Psoriasis, or all of them as a file.
02

Study summary

This is an open-label, long-term safety study of roflumilast (ARQ-151) 0.3% cream in subjects with chronic plaque psoriasis involving up to 25% total Body Surface Area (BSA). Study medication will be applied by the qualifying subjects topically once daily for 52 weeks at home. Periodic clinic visits will include assessments for clinical safety, application site reactions, and disease improvement or progression.

Read the detailed description

Cohort 1 of this study consisted of participants who previously completed study ARQ-151-201 (NCT03638258), and Cohort 2 consisted of participants who were not previously enrolled in ARQ-151-201.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants legally competent to sign and give
  2. Males and females ages 18 years and older
  3. Subjects with chronic plaque psoriasis who met eligibility criteria for ARQ-151-201, successfully completed ARQ-151-201 through Week 12, and are able to enroll into this long-term safety study on the Week 12 visit of the previous study (ARQ-151-201).
  4. Females of (FOCBP) must have a negative urine pregnancy test at all study visits. In addition, sexually active FOCBP must agree to use at least one form of highly effective throughout the trial. Highly effective forms of contraception include: oral/implant/injectable/transdermal contraceptives, intrauterine device, or partner's vasectomy. If barrier methods are used (e.g., condom with spermicide, diaphragm with spermicide), then 2 forms of conception are required. The use of abstinence as a contraceptive measure is acceptable as long as this is a consistent part of a lifestyle choice and a backup method has been identified if the subject becomes sexually active.
  5. women with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization (permanent sterilization methods include hysterectomy, bilateral oophorectomy, hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy).

Exclusion criteria

Exclusion Criteria:

  1. Subjects who experienced an ARQ-151 treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-151 cream in Study ARQ-151-201.
  2. Subjects that use any Excluded Medications and Treatments
  3. Current diagnosis of guttate, erythrodermic/exfoliative, palmoplantar, or pustular psoriasis.
  4. Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin during the study period.
  5. Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, , barbiturates (including phenobarbital), phenytoin, and rifampin during the study period.
  6. Known or suspected:

    • severe renal insufficiency or severe hepatic disorders
    • to component(s) of the products
    • history of severe depression, suicidal ideation
  7. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  8. Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  9. Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.
  10. Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
  11. Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
332 participants (actual)

Study arms

  • Other
    Long-term Safety of Roflumilast

    Participants applied roflumilast (ARQ-151) cream 0.3% once daily for 52 weeks

    Drug: Roflumilast

Interventions

  • Roflumilast cream 0.3% for topical application

    Also known as: ARQ-151

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE)

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that began after initiating study treatment (treatment-emergent AEs \[TEAEs\]) in ARQ-151-202 are presented.

    Time frame: Up to 52 weeks

  2. Number of Participants Experiencing ≥1 Serious Adverse Event (SAE)

    An SAE is any AE that in the view of either the PI or Sponsor, results in any of the following outcomes: Death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Number of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'

    The number of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 12 is reported. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater plaque severity.

    Time frame: Weeks 12, 24, 36, and 52

  2. Duration of Response in Participants Achieving 'Clear' IGA Score

    The median time to re-starting study therapy among participants who achieve a 'clear' IGA score and stop treatment to all lesions is presented.

    Time frame: Up to 52 weeks

  3. Number of Participants With Intertriginous Area Involvement Achieving an Intertriginous Area Investigator Global Assessment (I-IGA) Score of "Clear' or 'Almost Clear'

    The number of participants who had intertriginous area involvement with an I-IGA score of 'clear' or 'almost clear' is presented. The I-IGA is 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater plaque severity.

    Time frame: Weeks 12, 24, 36, and 52

  4. Number of Participants Achieving a 75% Reduction From Baseline in Modified Psoriasis Severity Index (mPASI-75)

    The number of participants achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.

    Time frame: Baseline and Weeks 12, 24, 36, and 52

07

Results

Posted Aug 18, 2022

Participant flow

Participants were recruited at 30 study sites in the United States and Canada.

Participant flow — Overall Study
MilestoneCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Started230102
Completed16480
Not completed6622
Withdrew: Adverse event112
Withdrew: Lost to follow-up2410
Withdrew: Withdrawal by subject2610
Withdrew: Lack of efficacy30
Withdrew: Covid-19 disruption20

Outcome measures

PrimaryNumber of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE)

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that began after initiating study treatment (treatment-emergent AEs \[TEAEs\]) in ARQ-151-202 are presented.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE)
ParticipantsCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Number of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE)10460
PrimaryNumber of Participants Experiencing ≥1 Serious Adverse Event (SAE)

An SAE is any AE that in the view of either the PI or Sponsor, results in any of the following outcomes: Death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing ≥1 Serious Adverse Event (SAE)
ParticipantsCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Number of Participants Experiencing ≥1 Serious Adverse Event (SAE)82
SecondaryNumber of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'

The number of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 12 is reported. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater plaque severity.

Time frame:
Weeks 12, 24, 36, and 52
Reported as:
Count of participants · Participants
Number of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'
ParticipantsCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Week 129247
Week 247934
Week 366836
Week 526839
SecondaryDuration of Response in Participants Achieving 'Clear' IGA Score

The median time to re-starting study therapy among participants who achieve a 'clear' IGA score and stop treatment to all lesions is presented.

Time frame:
Up to 52 weeks
Reported as:
Median · weeks
Duration of Response in Participants Achieving 'Clear' IGA Score
weeksCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Duration of Response in Participants Achieving 'Clear' IGA Score8.0 (4.1 to 9.0)12.4 (3.0 to NA)
SecondaryNumber of Participants With Intertriginous Area Involvement Achieving an Intertriginous Area Investigator Global Assessment (I-IGA) Score of "Clear' or 'Almost Clear'

The number of participants who had intertriginous area involvement with an I-IGA score of 'clear' or 'almost clear' is presented. The I-IGA is 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater plaque severity.

Time frame:
Weeks 12, 24, 36, and 52
Reported as:
Count of participants · Participants
Number of Participants With Intertriginous Area Involvement Achieving an Intertriginous Area Investigator Global Assessment (I-IGA) Score of "Clear' or 'Almost Clear'
ParticipantsCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Week 121115
Week 241314
Week 361310
Week 52910
SecondaryNumber of Participants Achieving a 75% Reduction From Baseline in Modified Psoriasis Severity Index (mPASI-75)

The number of participants achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.

Time frame:
Baseline and Weeks 12, 24, 36, and 52
Reported as:
Count of participants · Participants
Number of Participants Achieving a 75% Reduction From Baseline in Modified Psoriasis Severity Index (mPASI-75)
ParticipantsCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Week 126763
Week 2411457
Week 3613055
Week 5212461

Adverse events

Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Study 201 Participants0/230 (0%)8/230 (3.5%)15/230 (6.5%)
Cohort 2: Non-study 201 Participants0/102 (0%)2/102 (2%)7/102 (6.9%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Supraventricular tachycardiaCardiac disorders0/2301/102
Device failureProduct Issues0/2301/102
Atrioventricular block completeCardiac disorders1/2300/102
Cardiac failure congestiveCardiac disorders1/2300/102
Myocardial infarctionCardiac disorders1/2300/102
IleusGastrointestinal disorders1/2300/102
SepsisInfections and infestations1/2300/102
Femur fractureInjury, poisoning and procedural complications1/2300/102
SARS-CoV-2 test positiveInvestigations1/2300/102
HyponatraemiaMetabolism and nutrition disorders1/2300/102
Most frequent other events
Most frequent other events
EventCohort 1: Study 201 ParticipantsCohort 2: Non-study 201 Participants
Upper respiratory tract infectionInfections and infestations15/2307/102

Baseline characteristics

Baseline was defined as the last observation prior to administration of ARQ-151 cream. Thus the baseline assessments for participants in Cohort 1 assigned to ARQ-151 cream occurred in the ARQ-151-201 study, whereas baseline occurred in this study (ARQ-151-202) for vehicle cream participants in the 201 study and Cohort 2 participants.

Age, Continuous
Age, Continuous(years)Cohort 1: Study 201 ParticipantsCohort 2: Non-study 201 ParticipantsTotal
Mean55.3 ± 13.5252.7 ± 15.6454.5 ± 14.23
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Study 201 ParticipantsCohort 2: Non-study 201 ParticipantsTotal
Female10446150
Male12656182
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Study 201 ParticipantsCohort 2: Non-study 201 ParticipantsTotal
Hispanic or Latino461763
Not Hispanic or Latino18484268
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Study 201 ParticipantsCohort 2: Non-study 201 ParticipantsTotal
American Indian or Alaska Native000
Asian13619
Black or African American24529
Native Hawaiian or Other Pacific Islander011
White18385268
Multiple/Other10515
Modified Psoriasis Area Severity Index (mPASI)
Modified Psoriasis Area Severity Index (mPASI)(score on a scale)Cohort 1: Study 201 ParticipantsCohort 2: Non-study 201 ParticipantsTotal
Mean5.42 ± 3.7004.50 ± 3.8215.14 ± 3.755
08

Study locations

30 sites
  • Arcutis Clinical Site 35
    Beverly Hills, California 90212, United States
  • Arcutis Clinical Site 29
    Northridge, California 91324, United States
  • Arcutis Clinical Site 28
    San Diego, California 92123, United States
  • Arcutis Clinical Site 27
    Santa Monica, California 90403, United States
  • Arcutis Clinical Site 12
    Miami, Florida 33144, United States
  • Arcutis Clinical Site 16
    Sanford, Florida 32771, United States
  • Arcutis Clinical Site 21
    Louisville, Kentucky 40217, United States
  • Arcutis Clinical Site 34
    Clinton Township, Michigan 48038, United States
  • Arcutis Clinical Site 33
    Detroit, Michigan 48202, United States
  • Arcutis Clinical Site 20
    Fridley, Minnesota 55432, United States
  • Arcutis Clinical Site 22
    New York, New York 10029, United States
  • Arcutis Clinical Site 14
    High Point, North Carolina 27262, United States
  • Arcutis Clinical Site 39
    Bexley, Ohio 43209, United States
  • Arcutis Clinical Site 15
    Pittsburgh, Pennsylvania 15213, United States
  • Arcutis Clinical Site 19
    College Station, Texas 77845, United States
  • Arcutis Clinical Site 37
    Houston, Texas 77004, United States
  • Arcutis Clinical Site 13
    Houston, Texas 77056, United States
  • Arcutis Clinical Site 23
    San Antonio, Texas 78213, United States
  • Arcutis Clinical Site 24
    Webster, Texas 77598, United States
  • Arcutis Clinical Site 31
    Norfolk, Virginia 23502, United States
  • Arcutis Clinical Site 18
    Surrey, British Columbia V3R 6A7, Canada
  • Arcutis Clinical Site 11
    Surrey, British Columbia V3V 0C6, Canada
  • Arcutis Clinical Site 38
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Arcutis Clinical Site 10
    Ajax, Ontario L1S 7K8, Canada
  • Arcutis Clinical Site 25
    London, Ontario N6H 5L5, Canada
  • Arcutis Clinical Site 26
    Markham, Ontario L3P 1X2, Canada
  • Arcutis Clinical Site 32
    Oakville, Ontario L6J 7W5, Canada
  • Arcutis Clinical Site 17
    Peterborough, Ontario K9J 5K2, Canada
  • Arcutis Clinical Site 30
    Waterloo, Ontario N2J 1C4, Canada
  • Arcutis Clinical Site 36
    Windsor, Ontario N8W 1E6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Oct 2020, 21 months.

Results were first posted in Aug 2022, 1 year 10 months after primary completion. A results delay was requested in Sep 2021.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 21 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2018
First posted
Dec 5, 2018
StartActual
Dec 18, 2018
Primary completionActual
Oct 8, 2020
CompletionActual
Oct 8, 2020
Results delay requested
Sep 29, 2021
Results first posted
Aug 18, 2022
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03764475
Responsible party
Sponsor
First posted
Dec 5, 2018
Start date
Dec 18, 2018
Primary completion
Oct 8, 2020
Completion
Oct 8, 2020
Results posted
Aug 18, 2022
Last update
Sep 2, 2022

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion